for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Axsome Therapeutics Inc

AXSM.O

Latest Trade

28.52USD

Change

-1.66(-5.50%)

Volume

537,880

Today's Range

28.38

 - 

31.49

52 Week Range

19.38

 - 

78.34

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
30.18
Open
30.30
Volume
537,880
3M AVG Volume
12.32
Today's High
31.49
Today's Low
28.38
52 Week High
78.34
52 Week Low
19.38
Shares Out (MIL)
37.69
Market Cap (MIL)
1,137.54
Forward P/E
-8.40
Dividend (Yield %)
--

Next Event

Q4 2021 Axsome Therapeutics Inc Earnings Release

Latest Developments

More

Axsome Therapeutics Provided A Response To FDA Addressing 2 Deficiencies Related To NDA For AXS-05

Axsome Therapeutics Reports Third Quarter 2021 Financial Results And Provides Business Update

Axsome Therapeutics Expands Term Loan Facility With Hercules Capital To $300 Mln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Axsome Therapeutics Inc

Axsome Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders. The Company's core CNS portfolio includes five product candidates, which includes AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14. AXS-05 is an oral N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity for the treatment of major depressive disorder (MDD). AXS-07 is an oral multi-mechanistic medicine for the acute treatment of migraine. AXS-07 consists of MoSEIC (Molecular Solubility Enhanced Inclusion Complex) meloxicam and rizatriptan. AXS-09 is an oral NMDA receptor antagonist with multimodal activity consisting of esbupropion and dextromethorphan for the treatment of CNS disorders. AXS-12, reboxetine, is an oral medicine in development for the treatment of narcolepsy. AXS-14, esreboxetine is an oral medicine in development for the treatment of fibromyalgia.

Industry

Biotechnology & Drugs

Contact Info

22 CORTLANDT STREET, 16TH FLOOR

NEW YORK, NY

10007

United States

+1.212.3323241

http://axsome.com/

Executive Leadership

Herriot Tabuteau

Chairman of the Board, President, Chief Executive Officer, Founder

Nick Pizzie

Chief Financial Officer

Mark L. Jacobson

Chief Operating Officer

Kevin Laliberte

Executive Vice President - Product Strategy

Lori Englebert

Senior Vice President - Commercial and Business Development

Key Stats

1.87 mean rating - 15 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-1.150

2019

-2.010

2020

-2.770

2021(E)

-3.594
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
26.63
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
115.11
LT Debt To Equity (MRQ)
115.11
Return on Investment (TTM)
-91.28
Return on Equity (TTM)
-78.44

Latest News

Latest News

Axsome says U.S. FDA asks for no extra data for depression drug, shares surge

Axsome Therapeutics Inc said on Monday the U.S. Food and Drug Administration did not ask for additional information on the company's drug to treat depression as the agency continues to review it, sending shares of the drug developer surging 44% before the bell.

U.S. FDA unable to complete review of Axsome depression drug by target action date

Axsome Therapeutics Inc said on Monday the U.S. Food and Drug Administration (FDA) was not able to complete its review of the company's drug to treat major depressive disorder by the target action date of Aug. 22.

BRIEF-Axsome Therapeutics Receives FDA Breakthrough Therapy Designation For AXS-05

* AXSOME THERAPEUTICS RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR AXS-05 FOR THE TREATMENT OF ALZHEIMER’S DISEASE AGITATION Source text for Eikon: Further company coverage:

BRIEF-Axsome Therapeutics Presents Data From Gemini Phase 3 Trial Of AXS-05 In Major Depressive Disorder

* AXSOME THERAPEUTICS PRESENTS DATA FROM GEMINI PHASE 3 TRIAL OF AXS-05 IN MAJOR DEPRESSIVE DISORDER AT THE 2020 AMERICAN SOCIETY FOR CLINICAL PSYCHOPHARMACOLOGY ANNUAL MEETING Source text for Eikon: Further company coverage:

BRIEF-Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint In In Alzheimer’S Disease Agitation

* AXSOME THERAPEUTICS ANNOUNCES AXS-05 ACHIEVES PRIMARY ENDPOINT IN THE ADVANCE-1 PIVOTAL PHASE 2/3 TRIAL IN ALZHEIMER’S DISEASE AGITATION

BRIEF-Axsome Therapeutics Announces Axs-07 Achieves Both Co-Primary Endpoints

* AXSOME THERAPEUTICS ANNOUNCES AXS-07 ACHIEVES BOTH CO-PRIMARY ENDPOINTS AND PREVENTS MIGRAINE PAIN PROGRESSION IN THE INTERCEPT PHASE 3 TRIAL IN THE EARLY TREATMENT OF MIGRAINE

BRIEF-Axsome Therapeutics Posts Q4 Loss Per Share Of $0.71

* AXSOME THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Axsome Therapeutics Announces Promotion Of Mark Jacobson To Chief Operating Officer

* AXSOME THERAPEUTICS ANNOUNCES THE PROMOTION OF MARK JACOBSON TO CHIEF OPERATING OFFICER Source text for Eikon: Further company coverage:

BRIEF-Axsome Therapeutics Completes Patient Enrollment In Intercept Phase 3 Trial Of Axs-07 In The Early Treatment Of Migraine

* AXSOME THERAPEUTICS COMPLETES PATIENT ENROLLMENT IN THE INTERCEPT PHASE 3 TRIAL OF AXS-07 IN THE EARLY TREATMENT OF MIGRAINE

Axsome shares surge 75% after depression drug reduces symptoms in late-stage study

Axsome Therapeutics Inc said on Monday its drug succeeded in reducing symptoms of major depressive disorder in a late-stage trial, taking the company a step closer to entering a multi-billion dollar market for depression treatments.

Axsome depression drug meets late-stage study goal

Axsome Therapeutics Inc said on Monday its drug succeeded in reducing symptoms of major depressive disorder in a late-stage trial, sending the company's share up 16% before the bell.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up